Opdivo
BMS Withdraws Opdivo Indication for HCC Monotherapy
In consultation with the FDA, Bristol Myers Squibb has voluntarily withdrawn from the U.S. market the indication ...
JULY 30, 2021
FDA Grants New Indication for Opdivo for Resected Esophageal or GEJ Cancer
The FDA granted a new indication for nivolumab (Opdivo, Bristol Myers Squibb) for the treatment of patients with ...
JUNE 7, 2021
Opdivo Approved for First-Line Treatment of Advanced or Metastatic GI Cancers
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb), in combination with fluoropyrimidine- and ...
APRIL 27, 2021
FDA Grants New Indication for Opdivo + Yervoy in mCRC
The FDA granted a new indication for Bristol-Myers Squibb’s nivolumab (Opdivo) and ipilimumab (Yervoy) to ...
SEPTEMBER 6, 2018
Load more